Yoda Therapeutics Inc.
Update：2026/08/06
Industries
Main Industry
Biotechnology
Main Product/Service
Neurology
Pipeline
Utilizing Yoda’s proprietary AI-based drug screening platform, we engage in the exploration and development of promising and beneficial products to address unmet medical needs, instilling new hope in patients.YA-101 Multiple System Atro
Pipeline
Utilizing Yoda’s proprietary AI-based drug screening platform, we engage in the exploration and development of promising and beneficial products to address unmet medical needs, instilling new hope in patients.YA-101 Multiple System Atro
Founded Year
2022
Unified Business No.
89116715
Status
Active
Number of Employees
0
Total Paid-in
Capital
773,881,600 (NT$)
Location of Company
Taiwan
, Taipei City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Yoda Pharmaceuticals Inc. was founded in 2019 through a collaboration of researchers from National Taiwan University, National Yang Ming Chiao Tung University, and the National Health Research Institutes, along with psychiatric physicians in practice. Incubated through Taiwan's national initiative and Stanford University's global SPARK program, Yoda is a pharmaceutical company specializing in the use of state-of-the-art AI technology for the development of innovative drugs targeting Central Nervous System (CNS) disorders.
YA-101, Yoda's flagship drug, received orphan drug designation for Multiple System Atrophy (MSA) from the U.S. Food and Drug Administration (FDA) in 2022 and has entered phase I clinical trials. In addition, Yoda’s development pipeline includes new durgs in the field of neurological and psychiatric disorders and cerebrovascular diseases, targeting conditions such as schizophrenia, Alzheimer's disease, Parkinson‘s disease, Autism, ischemic stroke, and traumatic brain injury . Driven by a mission to address unmet medical needs, we are dedicated to offering new treatment options that are innovative, effective, safe, and convenient.
YA-101, Yoda's flagship drug, received orphan drug designation for Multiple System Atrophy (MSA) from the U.S. Food and Drug Administration (FDA) in 2022 and has entered phase I clinical trials. In addition, Yoda’s development pipeline includes new durgs in the field of neurological and psychiatric disorders and cerebrovascular diseases, targeting conditions such as schizophrenia, Alzheimer's disease, Parkinson‘s disease, Autism, ischemic stroke, and traumatic brain injury . Driven by a mission to address unmet medical needs, we are dedicated to offering new treatment options that are innovative, effective, safe, and convenient.
